Hospital Arnau de Vilanova-ko ikertzaileekin lankidetzan egindako argitalpenak (34)

2024

  1. Clinical profile and outcomes in very elderly patients with atrial fibrillation anticoagulated with rivaroxaban: data from the EMIR study

    Journal of Geriatric Cardiology, Vol. 21, Núm. 7, pp. 723-732

2023

  1. Impact of COVID-19 pandemic on the sanitary assistance of atrial fibrillation in Spain

    REC: CardioClinics, Vol. 58, Núm. 3, pp. 241-244

  2. Impact of the Spanish consensus for improving lipid control on patients admitted for an acute coronary syndrome

    Journal of Clinical Lipidology, Vol. 17, Núm. 6, pp. 756-764

  3. Use of Direct Acting Oral Anticoagulants in Elderly Patients with Atrial Fibrillation: A Multicenter, Cross-Sectional Study in Spain

    Journal of Clinical Medicine, Vol. 12, Núm. 3

2022

  1. Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study

    Cardiology Journal, Vol. 29, Núm. 6, pp. 936-947

  2. Knowledge of the clinical cardiologist on high-risk type 2 diabetes mellitus. What do we know and how can we improve?

    REC: CardioClinics, Vol. 57, Núm. 4, pp. 263-270

  3. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study

    Cardiology Journal, Vol. 29, Núm. 4, pp. 601-609

  4. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry

    European heart journal. Cardiovascular pharmacotherapy, Vol. 9, Núm. 1, pp. 38-46

  5. Prognostic value of a model based on IC-BERG recommendations in ambulatory patients with heart failure

    REC: CardioClinics, Vol. 57, Núm. 2, pp. 76-84

  6. Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries

    Journal of comparative effectiveness research, Vol. 11, Núm. 16, pp. 1173-1184

  7. Selection of the best of 2021 in clinical cardiology and COVID-19

    REC: CardioClinics, Vol. 57, pp. S17-S22

  8. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study

    European Journal of Clinical Investigation

2021

  1. Recommendations to improve lipid control in primary prevention patients. A consensus document of the Spanish Society of Cardiology

    REC: CardioClinics, Vol. 56, Núm. 2, pp. 118-128

  2. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review

    Diabetic Medicine, Vol. 38, Núm. 3

  3. Selection of the best of 2020 on antithrombotic treatment for the clinical cardiologist

    REC: CardioClinics, Vol. 56, pp. 54-58

  4. Soft skills in cardiology telemedicine consultations. Response

    Revista Espanola de Cardiologia

  5. Telematic cardiology consultation in the elderly. The 5 M framework can help. Response

    Revista Espanola de Cardiologia

  6. Telemedicine for patients with valvular heart disease or aortic disease in the era of COVID-19. Response

    Revista Espanola de Cardiologia

  7. Telemedicine, ethics, and law in times of COVID-19. A look towards the future

    Revista Clinica Espanola, Vol. 221, Núm. 7, pp. 408-410

  8. Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: Impact of inappropriate doses (the EMIR study)

    Journal of Comparative Effectiveness Research, Vol. 10, Núm. 7, pp. 583-593